Epitalon Side Effects and Potentially Permanent Side Effects: What the Evidence Actually Shows

Does epitalon have any documented side effects?

FDA's July 2026 evaluation found three human studies of epitalon: two of a sublingual spray in night-shift workers and one of injections beside the eye in retinitis pigmentosa. None was a safety study, and the agency found no clinical study that assessed epitalon's safety [2]. Its search of the adverse-event database through December 8, 2025, and of the food and supplement complaint system through December 5, 2025, retrieved no epitalon reports [2].

Those results do not establish that reactions cannot occur. Epitalon is not an approved drug and has no label, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before they are marketed [2][5].

A 2026 narrative review of epitalon and epithalamin reached a similar position: human evidence is limited to small physiological or biomarker studies plus an older controlled retinitis pigmentosa study, no adequately powered randomized trial has established efficacy, and pharmacokinetic, dose-ranging and long-term safety data remain inadequate [1].

What the human studies actually measured

The most detailed study was placebo-controlled, in healthy women aged 40 to 50 who were mostly night-shift workers. Seventy-five women were enrolled; 40 had low melatonin output and were split into two groups of 20. They used a sublingual Ala-Glu-Asp-Gly spray delivering about 0.5 mg per day, or placebo, for 20 days. Urinary 6-sulfatoxymelatonin rose about 1.7-fold with epitalon and did not change with placebo, and 83% versus 25% were described as improved in mood and physical condition [2].

No sleep outcomes were measured, blinding was not specified, and the study was short and small. It gave no safety data [2].

That melatonin result is the closest thing to a measured hormonal effect in people. Small studies report that epitalon raises melatonin output in older or pineal-impaired subjects, and FDA found that how epitalon changes melatonin in the body is unknown [2]. The shift-work study measured a urinary melatonin metabolite, not sleep [2].

The retinitis pigmentosa study is older. Its abstract reports a positive clinical effect in 90% of cases in patients with degenerative retinal lesions but gives no sample size, outcome counts or design details, and it has not been replicated [6][2]. Epitalon was injected beside the eye in that study [2].

The two concerns that can be named

The first is cancer. In cultured human fetal fibroblasts that lack telomerase, epitalon induced the catalytic subunit of telomerase, telomerase activity and telomere elongation [4]. FDA warned that, since epitalon activates telomerase and lengthens telomeres, and longer telomeres are generally linked to a higher cancer risk, it has a mechanistic potential to be carcinogenic [2]. That is a mechanism-based warning, not an observed cancer signal in people. The 2026 review lists oncologic uncertainty around epitalon as unresolved [1].

The second is immunogenicity. FDA raised an immunogenicity concern for subcutaneous epitalon, and its compounding page notes that injectable peptides may pose immunogenicity risk from aggregation and peptide-related impurities [2][3].

Animal data are sometimes presented as reassurance. In a mouse lifespan study, Anisimov and colleagues injected female SHR mice with 1.0 microg per mouse, roughly 30 to 40 microg/kg, on 5 consecutive days each month from age 3 months until natural death, with 54 mice per group [7]. In that study, mean lifespan, body weight and total spontaneous tumor incidence did not differ from controls [7]. Chromosome aberrations in bone marrow cells fell 17.1% (P<0.05), leukemia was 6.0-fold lower, and the lifespan of the last 10% of survivors rose 13.3% with maximum lifespan up 12.3% [7]. FDA judged the mouse studies of cancer and chromosome damage too limited to establish safety, pointing to a single fixed dose, female-only animals and short exposure [2].

Dose and labeling

No approved dose of epitalon exists [2]. Websites FDA reviewed suggest 5 mg to 10 mg per day by subcutaneous injection or orally in cycles; that is marketing, not evidence [2]. The human studies used a sublingual spray delivering about 0.5 mg per day for 20 days and a parabulbar, or beside-the-eye, injection for retinitis pigmentosa [2]. FDA found no pharmacokinetic data for epitalon [2].

Because there is no approved product, there is no label listing warnings or interactions.

What the regulatory status means for safety information

Epitalon is not an FDA-approved drug and is not a component of one. FDA's review found no USP or National Formulary monograph, no listing in the European or Japanese pharmacopeias, and no approved product in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, or authorized by the European Medicines Agency [2].

On compounding, FDA's page on bulk substances that may raise significant safety risks lists epitalon in its table of substances previously in category 2 whose nominators withdrew them. FDA states that it has not identified safety-related information regarding epitalon for the proposed route of administration, and that injectable peptides may pose immunogenicity risk. Removal from category 2 was not a finding that epitalon is safe [3]. Epitalon appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians, or on FDA's list for outsourcing facilities [8][9][10].

FDA staff proposed that epitalon not be added to the pharmacy bulks list; FDA evaluated only insomnia and found no evidence of effectiveness for it and no clinical safety data [2]. FDA's Pharmacy Compounding Advisory Committee nonetheless voted on July 24, 2026 in favor of adding epitalon to the bulks list [11][5]. That vote is advice only and is not binding, and epitalon is not on the list [5]. HHS's draft enforcement-discretion policy for six peptides, filed in October 2026, says HHS does not intend to take enforcement action against certain pharmacies, facilities and physicians compounding epitalon acetate for subcutaneous or intramuscular use in intermittent courses if its conditions are met, but the notice states that it does not establish rights for any person and is not binding on HHS or the public [5][12].

Neither the advisory vote nor the draft policy is an approval, a listing, or a finding that epitalon is safe [5].